Navigation Links
AutoImmune Inc. Files Certificate of Dissolution and Completes Sale of Colloral® Business; Trading of Common Stock to Cease After June 30, 2010
Date:6/30/2010

PASADENA, Calif., June 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (Pink Sheets: AIMM) today announced that it filed its Certificate of Dissolution with the Delaware Secretary of State on June 30, 2010 (the "Final Record Date"), in accordance with its previously announced Plan of Complete Liquidation and Dissolution. As a result of such filing, the company has closed its stock transfer books and will discontinue recording transfers of its common stock, except by will, intestate succession or operation of law effective at the close of business on the Final Record Date.  All liquidating distributions from AutoImmune after the Final Record Date will be made to stockholders of record on the Final Record Date pro rata according to their holdings of common stock as of the Final Record Date.

In furtherance of the company's Plan of Complete Liquidation and Dissolution, the company has completed a sale of the assets of the Colloral® business, the company's joint venture with Deseret Laboratories, Inc.  As part of the sale transaction and dissolution process, Colloral LLC was merged with and into AutoImmune.

As previously announced, AutoImmune's business activities are now limited to those necessary to preserve the value of its assets, wind up its business and affairs, and distribute its assets in accordance with the Plan of Complete Liquidation and Dissolution.

About AutoImmune Inc.

AutoImmune is a biopharmaceutical company that has focused on the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

website: http://www.autoimmuneinc.com


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
2. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
3. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
4. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
5. Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
6. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
9. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
(Date:8/2/2017)... 2017   Marshall County Hospital in Benton, Kentucky has ... of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ... pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)... 1, 2017   CerSci Therapeutics , a non-opioid ... , has received notice from the National Institute ... Health (NIH) that it has been awarded a Direct-to-Phase ... $650,000 in 2017 with an additional $1,000,000 to follow ... Drug application of their lead non-opioid drug candidate CT-044 ...
Breaking Medicine Technology:
(Date:8/21/2017)... Yorba Linda, Ca (PRWEB) , ... August 22, ... ... for numerous industries, but not without risk to health and safety. By learning ... risks could be eliminated. , In this webinar, attendees will gain a ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior assisted living homes ... , Guests will be able to vote for their favorite Chef among the ... Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea ...
(Date:8/21/2017)... ... August 21, 2017 , ... The American Hospital Association (AHA) has ... Highmark Health company, to its Board of Trustees for a three-year term beginning January ... care provider organizations and individuals that are committed to the improvement of health in ...
(Date:8/20/2017)... Land Texas (PRWEB) , ... August 20, 2017 ... ... announce that the HIPAA ComplyPAK™ Compliance Management System has assisted multiple ... Institute of Certified Public Accountants, Service Organization Control Level 2 (AICPA SOC Level ...
(Date:8/19/2017)... California (PRWEB) , ... August 18, 2017 , ... ... a partnership aimed at creating a transparent, verifiable database to help the cannabis ... distributed ledger technology, Paragon hopes to deliver a faster technology with lower fees. ...
Breaking Medicine News(10 mins):